면역보조제의 작용 및 개발

참고문헌 (99)

1. "Sur l'augmentation anormale de l'antitoxine chez les cheveux producteurs de serum antidiphterique", 101, pp.227~234 (1925)
2. "Procedres pour acroitre la production des antitoxines", 40, pp.1~10 (1926)
3. "The antigenic value of toxoid precipitated by potassium alum", 29, pp.38~45 (1926)
4. "Sensitization and antibody formation bacilli and parafin oil", 37, pp.509~513 (1937)
5. "Studies on the O antigen of Salmonella typhosa V Enhancement of antibody response to protein antigens by the purified lipopolysaccharide", pp.225~246 (1956)
6. "Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives", 59, pp.1317~1325 (1974)
7. "Immunoadjuvant activity of synthetic N-acetyl muramyl dipeptide", 34, pp.1363~1364 (1978)
8. "Saponin adjuvant induction of ovalbumin-specific CD8 cytotoxic T lymphocyte responses", 148, pp.2357~2362 (1992)
9. "A summary compendium of vaccine adjuvants and excipients" (1995), Plenum Publishing Corp.
10. "Immunological adjuvants:Desirable properties and side-effects", 28, pp.279~284 (1991)
11. "Design and selection of vaccine adjuvants:animal models and human trials", 3, pp.56~64 (2002)
12. "Adjuvants for human vaccines--current status, problems and future prospects", 13, pp.1263~1276 (1995)
13. "Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes", 154, pp.393~406 (1994)
14. "Presentation of exogenous antigens by macrophages:analysis of major histocompatibility complex class I and II presentation and regulation by cytokines", 24, pp.2421~2428 (1994)
15. "Detoxification of microbial toxins with glutaraldehyde and their use in the preparation of vaccines", pp.~1065 (1978), Pergamon Press
16. "Preparation of vaccines by the action of glutaraldehyde on toxins Methods in Enzymology", pp.~60 (1983), Academic Press
17. "Enhanced immunogenicity of cationized proteins Topics in Vaccine Adjuvant Research", pp.~107 (1991), CRC Press
18. "Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites", pp.16 257~22 259 (1987)
19. "Obsenrations on the antigenicity and clinical effects of a candidate anti-pregnancy vaccine:beta subunit of human chorionic gonadotropin linked to tetanus toxoid", 34, pp.328~335 (1980)
20. "Polysaccharide-protein conjugates:a new generation of vaccines", 161, pp.821~832 (1990)
21. "Characterization of anti-cerebroside sulfate antisera using a theoretical model to analyse liposome immune lysis data", 24, pp.1135~1143 (1987)
22. "Characteristics of cytotoxic T-lymphocytes directed to influenza virus haemagglutinin elicited by immunisation with muramyl dipeptide-influenza liposome vaccine", 41, pp.1~10 (1995)
23. "Paracrine cytokine adjuvants in cancer immunotherapy", 13, pp.399~415 (1995)
24. "Cytokines as immunological adjuvants", 10, pp.427~434 (1992)
25. "Vaccine adjuvants", 2, pp.370~383 (1980)
26. "Overview of vaccine adjuvants:present and future", 20, pp.7~12 (2002)
27. "Induction of CD8 cytotoxic cells by immunization with purified HIV-1 envelope protein in ISCOMs", 344, pp.873~875 (1990)
28. "Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles:the role of endogenous interleukin 1 in proliferative responses", 121, pp.134~145 (1989)
29. "Helper T cell subsets for immunoglobulin A responses oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues", xu-ama kiyo(j h), pp.1309~1320 (1993)
30. "The mode of action of immunological adjuvants", 92, pp.3~11 (1998)
31. "Enhanced antibody responses to liposome-associated protein antigens:preferential stimulation of IgG2a", b production, 1992, pp.10, 151~158
32. "IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response.", 156, pp.887~894 (1996)
33. "Helper T cell subsets for immunoglobulin A responses:oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues", 178, pp.1309~1320 (1993)
34. "Interleukin-10 is expressed by bovine type 1 helper and unrestricted parasite-specific T-cell clones and inhibits proliferation of all three subsets in an accessory-cell-dependent manner", pp.4697~4708 (1994)
35. "Aluminum compounds as vaccine adjuvants", 32, pp.155~172 (1998)
36. "Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles", 11, pp.965~969 (1993)
37. "Immune responses to ISCOMw formulations in animal and primate models", 19, pp.2661~2665 (2001)
38. "Development of a guinea-pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines", 13, pp.525~531 (1995)
39. "Development of a guinea-pig model for potency", immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines., 1996, pp.86, 283~296
40. "Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs:toxoid precipitated with alum", 34, pp.267~275 (1931)
41. "Diphtherie-Toxin zu adsorbieren", pp.2174~2178 (1931)
42. "Purification and adsorption of diphtheria toxoid", pp.350~158 351 (1946)
43. "Adjuvant effects of amorphous silica and of aluminium hydroxide on IgE and IgGl antibody production in different inbred mouse strains", 61, pp.253~258 (1980)
44. "ISCOMs and other saponin based adjuvants", 32, pp.247~271 (1998)
45. "Characteristics and practical use of new-generation adjuvants as an acceptable alternative to Freund's complete adjuvant", 143, pp.475~477 (1992)
46. "The formation of anti-sheep hemolytic amboceptor in the normal and tuberculous guinea pig" (1924)
47. "Synthesis of some new analogs of the immunoadjuvant glycopeptide MDP(Nacetyl-muramyl-L-alanyl- Disoglutamine", 11, pp.289~296 (1978)
48. "Modulation of expression of class II MHC and CD40 molecules in murine B cells by various muramyl dipeptides", 169, pp.75~84 (1996)
49. "A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A", 256, pp.567~579 (1990)
50. "Monophosphoryl lipid A as an adjuvant:past experiences and new directions", 6, pp.495~524 (1995)
51. "A study of the isolation and characterization of the saponin quil A Evaluation of its adjuvant activity with a special reference to the application in the vaccination of cattle against foot-and-mouth disease", pp.~40 (1978), Dalsgaard K
52. "Interleukin 2 acts as an adjuvant to enhance the potency of inactivated rabies vaccine", 86, pp.4240~4243 (1989)
53. "Involvement of gamma interferon in antibody enhancement by adjuvants", 58, pp.427~432 (1990)
54. "The adjuvant effect of interleukin-12 in a vaccine against Leishmania major", 263, pp.235~237 (1994)
55. "Application to man of vaccines consisting of emulsions in fatty substances", pi(y), pp.352~358 (1916)
56. "Dendritic cells internalize vaccine adjuvant after intramuscular injection", 186, pp.18~27 (1998)
57. "Liposomal adjuvanticity:effect of encapsulation and surface-linkage on antibody production and proliferative response", 17, pp.9~20 (1995)
58. "Cytotoxic T lymphocyte responses to a liposomeadjuvanted influenza A virus vaccine in the elderly", 172, pp.1103~1107 (1995)
59. "lmmunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A", 90, pp.2491~2495 (1992)
60. "lmmunogenicity of new virosome influenza vaccine in elderly people", 344, pp.160~163 (1994)
61. "Adjuvant activity of iscoms effect of ratio and co-incorporation of antigen and adjuvant", 14, pp.753~760 (1996)
62. "Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres", 14, pp.1442~1450 (1996)
63. "Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co- glycolide) microspheres", 63, pp.1195~1200 (1995)
64. "microspheres as antigen vehicles", lmmu(biology 184), pp.113~125 (1992)
65. "Adjuvants a classification and review of their modes of action", 15, pp.248~256 (1997)
66. "Comparison of adjuvant activities of aluminum phosphate calcium phosphate and stearyl tyrosine for tetanus toxoid", pp.53~22 63 (1994)
67. "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity", 186, pp.1623~1631 (1997)
68. "Evaluation of monophosphoryl lipid A as an adjuvant Enhancement of the serum antibody response in mice to polysaccharide- protein conjugates by concurrent injection with MPL", j immu(l 147), pp.2136~2140 (1991)
69. "Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems", 11, pp.1179~1184 (1993)
70. "Oral immunization of interleukin-4 knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4 Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses", 64, pp.1516~1525 (1996)
71. "The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity", 22, pp.2277~2281 (1992)
72. "Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin:role of the A subunit", 14, pp.260~266 (1996)
73. "LT(R192G) a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.", 16, pp.732~740 (1998)
74. "A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity is an effective mucosal adjuvant for intranasally delivered proteins", 63, pp.2100~2108 (1995)
75. "Regulation of DTH and IgE responses by IL-4 and IFN-gamma in immunized mice given pertussis toxin", 83, pp.639~645 (1994)
76. "Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives", 59, pp.1317~1325 (1974)
77. "Adjuvant modulation of immune responses to tuberculosis subunit vaccines", 65, pp.623~629 (1997)
78. "Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys", 23, pp.89~94 (1994)
79. "Dendritic cells internalize vaccine adjuvant after intramuscular injection", 186, pp.18~27 (1998)
80. "Clinical and immunologic responses to human immunodeficiency virus type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers", pp.1288~1291 (1994)
81. "Enhancement of humoral response against human influenza vaccine with the simple submicron oil", water emulsion adjuvant MF59, 1995, pp.13, 1557~1562
82. "Adjuvants-a balance between toxicity and adjuvanticity", 11, pp.294~306 (1993)
83. "Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection", 12, pp.200~209 (1994)
84. "Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys", 23, pp.89~94 (1994)
85. "Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses", 177, pp.69~76 (1997)
86. "Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen.", 66, pp.2859~2865 (1998)
87. "Synthetic lipopeptides incorporated in liposomes:in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen", 34, pp.569~576 (1997)
88. "Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres", 14, pp.1442~1450 (1996)
89. "Adjuvants influence the quantitative and quali-tative immune response in BALB", c mice immunized with respiratory syncytial virus FG subunit vaccine, 1997, pp.15, 525~532
90. "Mechanisms of action of nonionic block copolymer adjuvants", 2 (1994)
91. "Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly", 93, pp.189~203 (1997)
92. "The muramyl dipeptide analog GMTP- N-DPG preferentially induces cellular immunity to soluble antigens", 15, pp.1748~1752 (1997)
93. "Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide", 17, pp.117~131 (1995)
94. ., , 1998, 92~98
95. "Water- soluble phosphazene polymers for parenteral and mucosal vaccine delivery", 6, pp.473~493 (1995)
96. "Molecular adjuvants and immunomodulators:New approaches to immunization", 7, pp.277~289 (1994)
97. "Adjuvant effects of low doses of a nuclease resistant derivative of polyinosinic acid:polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine", 24, pp.160~166 (1978)
98. "Recent developments in adjuvants for vaccines against infectious diseases", 18, pp.69~85 (2001)
99. "Recent advances in veterinary vaccine adjuvants", 33, pp.469~478 (2003)